$AMRN - On our trading list, congrats to longs who have played this stock from $15 to $25. They have a few analyst comments today. Our take is to lock in some profits, but look for weakness to accumulate more. As always at Wild Tiger Trading use any volatility to make trades around your core positions. Amarin analyst commentary at Roth Capital Broad label approval for Vascepa 'clear win' for Amarin, says Roth Capital. Roth Capital analyst Yasmeen Rahimi said the FDA approved the broad label for Amarin's Vasepa two weeks ahead of the PDUFA date, saying that doctors will be in charge of which patients patients on stable statin therapy with established CV disease or diabetes plus two or more additional risk factors who have TG greater than150mg/dL should be placed on Vascepa to reduce CV risk. Rahimi says the inclusion of primary prevention without a specific checklist is a clear win for Amarin. The analyst maintains a Buy rating and $31 price target on Amarin shares. Amarin analyst commentary at H.C. Wainwright H.C. Wainwright keeps $51 target on Amarin with label meeting expectations. The FDA on Friday approved Amarin's Vascepa for an expanded label for cardiovascular risk reduction in elevated triglyceride patients. "We now have further clarity on the breakdown of labeling, which we interpret positively in terms of our expectations," H.C. Wainwright analyst Andrew Fein tells investors in a research note. He believes that characterization of triglyceride levels at 150mg/dL or higher did not come as a surprise, despite incorporation of patients with triglyceride levels as low as 135mg/dL in the REDUCE-IT trial. The analyst continues to think physicians can utilize their best judgment in assessing whether to assign the proven benefits of Vascepa in cardiovascular risk reduction when evaluating at-risk patients. Fein points out that his omega-3 proprietary physician survey indicated broad physician support for utilizing Vascepa with an expanded label in CV risk reduction. He reiterates a Buy rating on Amarin shares with a $51 price target. Fein maintains his current Vascepa sales revenue estimates of $416M in 2019 and $663M in 2020. Peak sales of Amarin's Vascepa being underappreciated, says Cantor Fitzgerald The FDA's approved patient population of Amarin's Vascepa is in-line with Street expectations, Cantor Fitzgerald analyst Louise Chen tells investors in a research note. The agency on Friday approved the use of Vascepa as an adjunctive therapy to reduce the risk of cardiovascular events among adults with elevated triglyceride levels of 150 milligrams per deciliter or higher. Vascepa is the first FDA approved drug to reduce CV risk among patients with elevated triglyceride levels as an add-on to maximally tolerated statin therapy, Chen points out. The analyst thinks the peak sales potential of Vascepa is underappreciated. Upward earnings revisions to levels not reflected in consensus expectations should drive Amarin shares higher, contends Chen. The analyst affirms an Overweight rating on the stock with a $35 price target. Amarin analyst commentary at Oppenheimer Amarin price target raised to $8 at Oppenheimer following label expansion. Oppenheimer analyst Leland Gershell raised his price target for Amarin to $8 from $7 following Friday's FDA approval of Vascepa to reduce cardiovascular event risk that came roughly two weeks ahead of its December 28 PDUFA date. In a research note to investors, Gershell says that while this is long-awaited for Amarin, he thinks constraints on the new indication appear to imply a target patient number of just 5M-8M, which he says is low compared to that anticipated by bulls. He maintains an Underperform rating, saying he is concerned that Street projections overestimate Amarin's profitability, especially in the out-years, the sizable M&A component of current valuation is at risk, and says investors will give increasing consideration to emerging competition within the prescription omega-3 class.Stifel 'taking profits' on Amarin following FDA approval, downgrades to HoldStifel analyst Derek Archila downgraded Amarin (AMRN) to Hold from Buy with a price target of $28, up from $26, after the FDA approved Vascepa for an expanded indication as an adjunct therapy in patients on statins with high triglycerides who have established CV disease and also for diabetic patients with greater than 2 cardiovascular risk factors. While he said "there is no doubt in our mind Vascepa will be a multi-billion dollar product," Archila prefers to "take profits" at the stock's current valuation near $11B fully diluted. He also points to unpredictability around Vascepa's intellectual property litigation, the drug's "relatively short" exclusivity period, and AstraZeneca's (AZN) Epanova CVOT results next year as downside risks. $AMRN, Amarin Corporation plc / H1 Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal. If you liked this article, please click the LIKE (thumbs up) button. Feel free to leave any comments, question, or opinions. (Sign-up if you haven't already done so). Follow us/bookmark us and check back occasionally for additional articles or comments on our page... Wild Tiger Trading - start/main page